Linking To And Embedding Dave Feldman’s “New KETO-CTA Data – Clarification and Update on Cleerly”

Today, I review, link to, and embed Dave Feldman‘s New KETO-CTA Data – Clarification and Update on Cleerly.

All that follows is from the above resource.

Aug 21, 2025 #cardiovascularhealth #ketodiet #cholesterol

In this talk, Dave Feldman shares new updates from the Keto-CTA study, comparing results across four independent CT imaging analyses: Cleerly, QAngio, HeartFlow, and semi-quantitative reads by expert readers. He addresses the controversies around LDL-C, ApoB, plaque progression, and regression, revealing why certain datasets conflict, and presents compelling evidence showing verified plaque regression in a subset of participants. (* This talk was provided courtesy of Symposium for Metabolic Health 2025. https://www.lowcarbusa.org/ )

0:00 – Intro & welcome

0:34 – Disclosures & background on the Keto-CTA study

1:01 – Study design & lean mass hyper-responder criteria

1:45 – CT scans, imaging methods & data acquisition

2:10 – Semi-quantitative vs quantitative analysis explained 3:06 – Timeline of analyses & initial expectations

3:29 – First Cleerly results & early concerns

4:11 – Shared findings: baseline plaque & lack of LDL/ApoB association

5:21 – Paper publication & critics’ reactions

6:07 – Prespecified methodology: why QAngio matters

6:59 – Social media debates & misinterpretations

7:33 – The “limited contrast” argument emerges

8:33 – Breaking down claims about “all high LDL”

9:42 – Visualizing the actual LDL spread

11:01 – LDL variability: 49 mg/dL to 591 mg/dL

12:30 – Problems with the “limited exposure” critique

13:08 – Revisiting the lipid hypothesis: dose-dependent effects 14:07 – Are these the “healthiest” participants? Context & caveats

15:14 – Participant risk factors: CAC scores, A1C, glucose, hs-CRP

16:33 – Why Dave reduced public debates for a time

17:01 – Issues discovered in Cleerly’s dataset

18:13 – Introducing HeartFlow: a blinded independent analysis 19:05 – Why a fourth analysis was critical

20:02 – Record-breaking multi-analysis study design

20:34 – Preliminary results warning

21:04 – Non-calcified plaque volume % change: conflicting findings

22:00 – Absolute vs relative change: why it matters

22:28 – Total plaque volume & percent atheroma volume

23:17 – How HeartFlow & QAngio compare to reference studies 24:40 – Top-level observations & agreements

25:07 – Plaque regression: the star of the show

26:14 – Direct verification of regression by Dr. Budoff

27:00 – Red flags in Cleerly’s data: no negative values

28:33 – The “noise floor” problem explained

30:28 – Why multiple analyses were necessary

31:15 – Every imaging study shows regression — except Cleerly 32:02 – Statistical implausibility of Cleerly’s results

32:37 – Final conclusions on regression evidence

33:29 – Does regression imply safety for lean mass hyper-responders?

34:11 – No association of LDL/ApoB with plaque presentation or progression

35:02 – What’s next: study extension & Triad study

35:38 – Reflecting on six years since Keto-CTA’s conception 36:32 – Acknowledgments & closing remarks